CTSO - Cytosorbents Corporation
6.48 -0.14 (-2.11%)
After hours: 4:23PM EDT
| Previous Close | 6.06 |
| Open | 6.07 |
| Bid | 6.60 x 3000 |
| Ask | 6.61 x 1200 |
| Day's Range | 6.07 - 6.63 |
| 52 Week Range | 5.84 - 14.95 |
| Volume | 81,882 |
| Avg. Volume | 117,592 |
| Market Cap | 213.488M |
| Beta (3Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.61 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
- PR Newswire•7 days ago
CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference
MONMOUTH JUNCTION, N.J. , June 11, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- Simply Wall St.•11 days ago
Does Market Volatility Impact Cytosorbents Corporation's (NASDAQ:CTSO) Share Price?
If you're interested in Cytosorbents Corporation (NASDAQ:CTSO), then you might want to consider its beta (a measure of...
- PR Newswire•15 days ago
CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference
MONMOUTH JUNCTION, N.J. , June 3, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- PR Newswire•29 days ago
CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference
MONMOUTH JUNCTION, N.J. , May 20, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to ...
- Zacks Small Cap Research•last month
CTSO: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust
Q1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. CytoSorbents (CTSO) reported financial results for their first quarter ending March 31st and provided a business update. While grant revenue was inline with expectations, product sales were a relative dud.
- Associated Press•last month
CytoSorbents: 1Q Earnings Snapshot
The Monmouth Junction, New Jersey-based company said it had a loss of 15 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•last month
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
MONMOUTH JUNCTION, N.J. , May 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•2 months ago
CytoSorbents to Report Q1 2019 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , May 1, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly ...
- PR Newswire•2 months ago
CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences
MONMOUTH JUNCTION, N.J. and BERLIN , April 24, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...
- PR Newswire•2 months ago
CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London
MONMOUTH JUNCTION, N.J. , April 8, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly ...
- PR Newswire•3 months ago
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
MONMOUTH JUNCTION, N.J., March 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that the Medical Device Division of the State of Israel Ministry of Health medical device regulation unit (AMAR), has granted registration of CytoSorb in Israel, clearing the way to begin selling the device in the country.
- Zacks Small Cap Research•3 months ago
CTSO: Q4 2018: Product Sales +27%, Expenses Jump In Part Due to Investments Aimed at Further Accelerating Growth
CytoSorbents (CTSO) reported financial results for their fourth quarter and fiscal year ending December 31st and provided a business update. Product revenue was driven by strong gains in both direct and distributor sales, the geographic footprints of both of which continue to expand. Unfortunately, much of the revenue and margin growth did not flow through the income statement in Q4 as new investments, aimed at further steepening the topline growth, resulted in the largest operating loss in company history.
Motley Fool•3 months agoCytosorbents Corp (CTSO) Q4 2018 Earnings Conference Call Transcript
CTSO earnings call for the period ending December 31, 2018.
- PR Newswire•3 months ago
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
2018 Total Revenue was $22.5 million , with 2018 Product Sales surpassing $20M for the first time, representing 51% growth over 2017 MONMOUTH JUNCTION, N.J. , March 7, 2019 /PRNewswire/ -- CytoSorbents ...
- PR Newswire•3 months ago
CytoSorbents to Present at the Cowen 39th Annual Health Care Conference
MONMOUTH JUNCTION, N.J. , March 6, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- PR Newswire•3 months ago
CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands
MONMOUTH JUNCTION, N.J., March 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has expanded direct sales of CytoSorb for all applications to Poland and the Netherlands, and for critical care applications in Sweden, Denmark, and Norway. As part of this effort, the company established CytoSorbents Poland Sp.
- PR Newswire•4 months ago
CytoSorbents to Report Fiscal 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , Feb. 28, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly ...
- PR Newswire•4 months ago
CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference
MONMOUTH JUNCTION, N.J. , Feb. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- PR Newswire•4 months ago
CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
MONMOUTH JUNCTION, N.J., Feb. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the 21st Annual BIO CEO & Investor Conference next week in New York City.
- Zacks Small Cap Research•4 months ago
CTSO: DSMB Recommends Continuance of REMOVE Study: Has several important implications
CytoSorbents (CTSO) announced this morning that the Data Safety Monitoring Board overseeing REMOVE, the company’s Germany-based study funded by the German government and which is evaluating safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery, recommended that the study continue. As a reminder, REMOVE is evaluating safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery.
- PR Newswire•4 months ago
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
MONMOUTH JUNCTION, N.J. , Feb. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- ACCESSWIRE•5 months ago
LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
- GlobeNewswire•5 months ago
Detailed Research: Economic Perspectives on Shell Midstream Partners, Interface, National Western Life Group, TPG Specialty Lending, Francesca's, and Cytosorbents — What Drives Growth in Today's Competitive Landscape
NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•5 months ago
CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care
MONMOUTH JUNCTION, N.J., Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced today that it has expanded its partnership with Fresenius Medical Care to Korea and Mexico. Under the terms of the agreement, Fresenius Medical Care has the exclusive rights to distribute CytoSorb for acute care and other hospital applications in Korea and Mexico.
- Simply Wall St.•5 months ago
Is Cytosorbents Corporation’s (NASDAQ:CTSO) CEO Pay Fair?
Phillip Chan became the CEO of Cytosorbents Corporation (NASDAQ:CTSO) in 2009. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the Read More...
